Moderna has announced plans to seek emergency authorization for its COVID-19 vaccine after data showed it to be 94.1 percent effective.
The company said it will apply for emergency use authorization from the Food and Drug Administration for its COVID-19 vaccine on Monday. This announcement comes after Moderna earlier this month revealed that preliminary phase-three trial data showed its vaccine candidate was almost 95 percent effective.
On Monday, Moderna said an analysis of 196 cases "confirms the high efficacy observed at the first interim analysis," and additionally, data also showed the vaccine was 100 percent effective at preventing severe COVID-19 cases.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Moderna is the second company to seek emergency authorization for a vaccine against COVID-19. Pfizer previously announced it would also be submitting a request for FDA emergency authorization for its vaccine candidate, which data showed was about 95 percent effective.
When COVID-19 vaccines begin to roll out, those at the highest risk are expected to receive them first. Moderna CEO Stéphane Bancel told The New York Times that should the company's vaccine receive emergency approval, the first doses could potentially be given by Dec. 21, and the company expects to produce 20 million doses in the United States by the end of the year.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.